JEFFREY KRUPA: Open Payments
NPI 1215646724 · WASHINGTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,580 in 55 payments from 8 companies in 2025. Trend: 2023 $303 · 2024 $924 · 2025 $1,580
Food & beverage: $1,468Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $374 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $286 |
| Janssen Pharmaceuticals, Inc | 11 | $267 |
| Axsome Therapeutics, Inc. | 3 | $260 |
| Neurocrine BioSciences, Inc. | 12 | $245 |
| Otsuka America Pharmaceutical, Inc. | 5 | $77 |
| ABBVIE INC. | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: CAPLYTA, INVEGA SUSTENNA, Auvelity, INGREZZA, AUSTEDO XR, UZEDY, ABILIFY MAINTENA, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
